Jove
Visualize
联系我们

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection.

Nature communications·2026
Same author

The Proteomics-Based Stratification of Obese Subjects Allows for a Second Selective Level Beyond Gender Classification.

International journal of molecular sciences·2026
Same author

CSPG4.CAR-T Cells Modulate Extracellular Matrix Remodeling in DMD Cardiomyopathy.

International journal of molecular sciences·2025
Same author

Glioblastoma: Overview of Proteomic Investigations and Biobank Approaches for the Development of a Multidisciplinary Translational Network.

Cancers·2025
Same author

A Holistic Investigation of Arabidopsis Proteomes Altered in Chloroplast Biogenesis and Retrograde Signalling Identifies PsbO as a Key Regulator of Chloroplast Quality Control.

Plant, cell & environment·2025
Same author

A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis.

Proceedings of the National Academy of Sciences of the United States of America·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Sep 18, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

490

解读放射治疗阻力:一种蛋白质学视角

Davide Perico1, Pierluigi Mauri1,2

  • 1Institute of Biomedical Technologies-National Research Council ITB-CNR, Via Fratelli Cervi 93, 20054 Milan, Italy.

Proteomes
|June 25, 2025
PubMed
概括

蛋白质组学可以识别生物标志物,预测癌症患者对放射治疗的反应,帮助克服治疗耐药性. 这种方法有助于制定精准瘤学策略,以获得更好的治疗结果.

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 生物化学 生物化学

背景情况:

  • 放射治疗耐药性是癌症治疗的一个主要挑战.
  • 了解放射电阻的分子机制对于有效的治疗至关重要.
  • 蛋白质组学为研究瘤异质性和治疗反应提供了一个强大的工具.

研究的目的:

  • 审查最近蛋白质组技术的进展,以识别放射敏感性和放射电阻的生物标志物.
  • 突出蛋白质组学在各种癌症类型中的应用,包括头,乳腺,肺癌和前列腺癌.
  • 讨论蛋白质组学在克服辐射抵抗和指导精确瘤学的潜力.

主要方法:

  • 基于质谱的蛋白质组学用于高通量,定量分析.
  • 生物信息集成用于生物标志物和途径识别.
  • 关于放射生物学中蛋白质组学应用的当前文献的综述.

主要成果:

  • 蛋白质组学可以确定调节放射电阻的关键机制,例如DNA修复,缺氧和代谢重编程.
  • 蛋白质组方法已经确定了在不同瘤类型中预测放射敏感性和放射电阻的潜在生物标志物.
  • 技术进步正在加强放射生物学的综合分析.
关键词:
生物标志物 生物标志物蛋白质组学 蛋白质组学无线电电阻的使用方法

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

相关实验视频

Last Updated: Sep 18, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

490
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

结论:

  • 蛋白质组学是精准医学的一个关键方法,用于了解瘤异质性和治疗反应.
  • 将蛋白质组学纳入放射治疗工作流程可以提高治疗效率,并最大限度地减少毒性.
  • 蛋白质组学的进一步进展将有助于克服辐射耐药性,并指导个性化癌症治疗策略.